for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-India's Biocon Says Itolizumab Receives DGCI Approval For Use In Moderate To Severe COVID-19 Patients

July 11 (Reuters) - Biocon Ltd:

* SAYS DRUG ITOLIZUMAB RECEIVES DRUGS CONTROLLER GENERAL OF INDIA’S APPROVAL FOR ITS USE IN MODERATE TO SEVERE COVID-19 PATIENTS

* BIOCON SAYS ITOLIZUMAB WILL BE MANUFACTURED AND FORMULATED AS AN INTRAVENOUS INJECTION AT CO’S BIO-MANUFACTURING FACILITY IN BENGALURU, INDIA Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up